IP Library Granted Patent US 8,673,295
Granted Patent B2
US 8,673,295 · App. 13/265,067 · Granted Mar 18, 2014

Thermoresponsive, biodegradable, elastomeric material and uses therefor

Inventors: Kazuro Lee Fujimoto (Pittsburgh, PA); Zuwei Ma (Woburn, MA); Jianjun Guan (Dublin, OH); William R. Wagner (Gibsonia, PA)
Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,673,295
App. No.
13/265,067
Granted
Mar 18, 2014
Kind
B2
Abstract

Provided are novel biocompatible copolymers and compositions comprising the copolymers. The copolymers are non-toxic and typically have an LCST below 37° C. Compositions comprising the copolymers can be used for wound treatment, as a cellular growth matrix or niche and for injection into cardiac tissue to repair and mechanically support damaged tissue. The copolymers comprise numerous ester linkages so that the copolymers are erodeable in situ. Degradation products of the copolymers are soluble and non-toxic. The copolymers can be amine-reactive so that they can conjugate with proteins, such as collagen. Active ingredients, such as drugs, can be incorporated into compositions comprising the copolymers.

Claims (7)

1. A method of growing cells comprising introducing cells into a copolymer having a lower critical solution temperature (LCST) of less than 37° C., consisting essentially of N-alkyl acrylamide residues in which the alkyl is one of methyl, ethyl, propyl, isopropyl and cyclopropyl; hydroxyethylmethacrylate (HEMA) residues; and polyactide-methacrylate macromere residues to produce a cell construct and incubating the cell construct under conditions suitable for growth of the cells.

2. The method of claim 1 , further comprising administering the cell construct into a patient.

3. The method of claim 1 , wherein the composition is administered to a patient and patient's cells migrate into the composition.

4. The method of claim 1 in which the composition comprises one or both of bFGF and IGF-I.

5. The method of claim 1 in which the composition is injected into a heart.

6. The method of claim 5 in which the heart comprises necrotic tissue.

7. The method of claim 6 in which the composition is injected into the heart approximately 2 weeks after a myocardial infarction.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 1, 2012
From: FUJIMOTO, KAZURO LEE; MA, ZUWEI; GUAN, JIANJUN; WAGNER, WILLIAM R.
To: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
Reel/Frame 027789/0906 →
CONFIRMATORY LICENSE Recorded Jan 5, 2012
From: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 027482/0452 →
Continuity (2)
Provisional Application 61174088 · Apr 30, 2009
Related Publication 20120156176A1 · Jun 21, 2012